Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma × axicabtagene ciloleucel × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 2 Recurrence 1 Lymphoma 1 HIV Infections 1

Interventions

Rituximab 53 Cyclophosphamide 53 fludarabine 35 fludarabine phosphate 29 Filgrastim 25 Etoposide 20 Melphalan 19 Gemcitabine 17 Bendamustine Hydrochloride 17 Vincristine 15 Cytarabine 15 Peripheral Blood Stem Cell Transplantation 14 Bortezomib 14 pembrolizumab 13 aldesleukin 13 Prednisone 13 Doxorubicin 12 Sirolimus 11 Busulfan 11 obinutuzumab 10 Whole-Body Irradiation 10 Vorinostat 10 Lenalidomide 10 Dexamethasone 10 Tacrolimus 9 sargramostim 8 romidepsin 8 Radiotherapy 8 Paclitaxel 8 Nivolumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡